The use of medication against attention deficit/hyperactivity disorder in Denmark: A drug use study from a patient perspective

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 589-598

  Pottegård, Anton ^a,b   Bjerregaard, Bine Kjøller ^c   Glintborg, Dorte ^b   Kortegaard, Lisbeth Sandal ^d   Hallas, Jesper ^a   Moreno, Søren Ilsøe ^b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b Danish Health and Medicines Authority   (Denmark)

^c DANISH MEDICINES AGENCY   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

ADHD; Atomoxetine; Denmark; Drug utilization; Methylphenidate; Psychostimulants

Indexed keywords

ANTICONVULSIVE AGENT; ATOMOXETINE; MELATONIN; METHYLPHENIDATE; MODAFINIL; NEUROLEPTIC AGENT;

ATTENTION DEFICIT DISORDER; CONTROLLED RELEASE FORMULATION; DENMARK; DRUG UTILIZATION; HUMAN; OFF LABEL DRUG USE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

ADOLESCENT; ADULT; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DENMARK; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; GUIDELINE ADHERENCE; HUMANS; KAPLAN-MEIER ESTIMATE; MEDICATION ADHERENCE; MIDDLE AGED; OFF-LABEL USE; PATIENT DROPOUTS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84877117524     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1344-0     Document Type: Review

References (48)

1. Gillberg C, Melander H, von Knorring AL, Janols LO, Thernlund G, Hagglof B et al (1997) Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 54(9):857-864
2. Hoza B, Gerdes AC, Mrug S, Hinshaw SP, Bukowski WM, Gold JA et al (2005) Peer-assessed outcomes in the multimodal treatment study of children with attention deficit hyperactivity disorder. J Clin Child Adolesc Psychol 34(1):74-86
3. Smith G, Jongeling B, Hartmann P, Russel C, Landau L (2010) Raine ADHD Study: Long-term outcomes associated with stimulant medication in the treatment of ADHD in children. Department of Health, Government of Western Australia, Perth
4. Comer JS, Olfson M, Mojtabai R (2010) National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 49(10):1001-1010
5. Fullerton CA, Epstein AM, Frank RG, Normand SL, Fu CX, McGuire TG (2012) Medication use and spending trends among children with ADHD in Florida's Medicaid Program, 1996-2005. Psychiatr Serv 63(2):115-121
6. Mojtabai R, Olfson M (2010) National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 67(1):26-36
7. Pottegard A, Bjerregaard B, Glintborg B, Hallas J, Moreno S (2012) The use of medication against Attention Deficit / Hyperactivity Disorder in Denmark: a drug utilization study in a national perspective. Eur J Clin Pharmacol. doi: 10.1007/s00228-012-1344-0
8. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish national prescription registry. Scand J Public Health 39(7 Suppl):38-41
9. WHO Collaborating Centre for Drug Statistics Methodology (2010) Guidelines for ATC classification and DDD assignment 2011. World Health Organization, Oslo
10. Hallas J, Gaist D, Bjerrum L (1997) The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 8(6):666-670
11. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish national prescription registry. Scand J Public Health 39(7 Suppl):38-41
12. Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T (2002) Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology 58(12):1826-1833
13. Polanczyk G, Rohde LA (2007) Epidemiology of attention-deficit/ hyperactivity disorder across the lifespan. Curr Opin Psychiatry 20(4):386-392
14. Pelham WE Jr, Fabiano GA, Massetti GM (2005) Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc Psychol 34(3):449-476
15. Brinkman WB, Sherman SN, Zmitrovich AR, Visscher MO, Crosby LE, Phelan KJ et al (2009) Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder. Pediatrics 124(2):580-589
16. DosReis S, Myers MA (2008) Parental attitudes and involvement in psychopharmacological treatment for ADHD: a conceptual model. Int Rev Psychiatry 20(2):135-141
17. DosReis S, Mychailyszyn MP, Evans-Lacko SE, Beltran A, Riley AW, Myers MA (2009) The meaning of attention-deficit/hyperactivity disorder medication and parents' initiation and continuity of treatment for their child. J Child Adolesc Psychopharmacol 19(4):377-383
18. Dowshen N, D'Angelo L (2011) Health care transition for youth living with HIV/AIDS. Pediatrics 128(4):762-771
19. Borus JS, Laffel L (2010) Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention. Curr Opin Pediatr 22(4):405-411
20. Leggett C, Hotham E (2011) Treatment experiences of children and adolescents with attention-deficit/hyperactivity disorder. J Paediatr Child Health 47(8):512-517
21. Hardy SE (2009) Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 7(1):34-59
22. Murray DW (2010) Treatment of preschoolers with attention-deficit/ hyperactivity disorder. Curr Psychiatry Rep 12(5):374-381
23. Agency for Healthcare Research and Quality (AHRQ) (2011) Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment. Comparative Effectiveness Review Number 44. AHRQ Publication No. 12-EHC003-EF. AHRQ, U.S. Department of Health and Human Services, Rockville
24. Swanson J, Arnold LE, Kraemer H, Hechtman L, Molina B, Hinshaw S et al (2008) Evidence, interpretation, and qualification from multiple reports of long-term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. J Atten Disord 12(1):15-43
25. Mannuzza S, Klein RG, Truong NL, Moulton JL III, Roizen ER, Howell KH et al (2008) Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 165(5):604-609
26. Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111(1):179-185
27. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW et al (2011) European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 20(1):17-37
28. Aagaard L, Hansen EH (2011) The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat 7:729-744
29. Salek RL, Claussen CM, Perez A, Dafny N (2012) Acute and chronic methylphenidate alters prefrontal cortex neuronal activity recorded from freely behaving rats. Eur J Pharmacol 679(1-3):60-67
30. Yang PB, Atkins KD, Dafny N (2011) Behavioral sensitization and cross-sensitization between methylphenidate amphetamine, and 3,4-methylenedioxymethamphetamine (MDMA) in female SD rats. Eur J Pharmacol 661(1-3):72-85
31. Callaghan RC, Cunningham JK, Sykes J, Kish SJ (2012) Increased risk of Parkinson's disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120(1-3):35-40
32. European Medicines Agency (2009) Elements recommended for inclusion in Summaries of Product Characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/Referrals-document/Methylphenidate-31/WC500011184.pdf
33. Pliszka S (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46(7):894-921
34. National Institute for Health and Clinical Excellence (2009) Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Available at: www.nice.org.uk/TA098
35. Børne-og Ungdomspsykiatrisk Selskab I Danmark (2008) Referenceprogram for udredning og behandling af børn og unge med ADHD. Available at: http://www.bupnet.dk/media/ADHDReferenceprogram080508-jsb[1].pdf
36. Pringsheim T, Steeves T (2011) Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Cochrane Database Syst Rev 13(4):CD007990
37. Wigal SB (2009) Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 23[Suppl 1]:21-31
38. Carlson GA, Dunn D, Kelsey D, Ruff D, Ball S, Ahrbecker L et al (2007) A pilot study for augmenting atomoxetine with methylphenidate: safety of concomitant therapy in children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health 1(1):10
39. Prasad S, Steer C (2008) Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder: clinical approaches and review of current available evidence. Paediatr Drugs 10(1):39-47
40. Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD et al (2007) Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder-a preliminary tolerability and efficacy study. Clin Ther 29(6):1168-1177
41. Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA et al (2007) Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. J Clin Pharmacol 47(12):1476-1488
42. Karlstad O, Nafstad P, Tverdal A, Skurtveit S, Furu K (2011) Comorbidities in an asthma population 8-29 years old: a study from the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.2233
43. Benjamin E, Salek S (2005) Stimulant-atypical antipsychotic interaction and acute dystonia. J Am Acad Child Adolesc Psychiatry 44(6):510-512
44. Hollis CP, Thompson A (2007) Acute dyskinesia on starting methylphenidate after risperidone withdrawal. Pediatr Neurol 37(4):287-288
45. Levine JB, Deneys ML, Benjamin S (2007) Dystonia with combined antipsychotic and stimulant treatment. J Am Acad Child Adolesc Psychiatry 46(6):665-666
46. Coskun M, Zoroglu S (2008) Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. J Clin Psychopharmacol 28(6):723-725
47. Spruyt K, Gozal D (2011) Sleep disturbances in children with attention-deficit/hyperactivity disorder. Expert Rev Neurother 11(4):565-577
48. Weiss MD, Salpekar J (2010) Sleep problems in the child with attention-deficit hyperactivity disorder: defining aetiology and appropriate treatments. CNS Drugs 24(10):811-828